Spinal muscular atrophy (SMA) is a progressive neurodegenerative disorder set in motion before birth. Scientists at St. Jude ...

Exercise can make a significant difference for patients with SMA by working alongside other medical advancements to improve ...

The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).

On this episode, an infant with a harrowing diagnosis defies all odds after receiving a $2 million genetic treatment. Then, a ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

A new electrical stimulation therapy for spinal muscle atrophy (SMA) has shown promise in reactivating motor neurons and ...

minimally invasive intervention targets the root cause of progressive loss of neural function in patients with spinal muscular atrophy (SMA), an inherited neuromuscular disease. The pilot trial in ...

The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...

Spinal muscle atrophy or SMA is a genetic disease that ... There is no cure. A gene therapy can save the lives of very young children with a severe form of the disease, and there are some ...

Boosting communication between the spinal nerves and the muscles using the spinal cord stimulation reverses spinal muscle ...

The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...